Frazier Life Sciences Acquisition Corp. II has priced a $75 million initial public offering of 7.5 million Class A shares at $10.00 per share. The SPAC, focused on life sciences targets, will begin trading on the Nasdaq Capital Market under the ticker FLSC on October 14, 2026.
Frazier Life Sciences Acquisition Corp. II, a special purpose acquisition company based in Palo Alto, California, announced on October 14, 2026, that it has priced its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share. The transaction raises a gross offering size of $75 million, positioning the vehicle to pursue a business combination with a target in the life sciences sector.
The Class A ordinary shares are scheduled to begin trading on The Nasdaq Capital Market under the ticker symbol "FLSC" on October 14, 2026. The company stated that the offering is expected to close on October 15, 2026, subject to customary closing conditions. This listing marks the latest entry in a steady stream of SPAC filings and IPOs observed in the market during early October 2026.
According to recent market data from SPACInsider, the SPAC market has remained active, with October 2026 already recording eight new business combinations, bringing the year-to-date total to 83. While the first full week of October was described as light on new IPOs, with only Pine Tree (NASDAQ:PAXGU) rolling into the market, the pricing of Frazier Life Sciences Acquisition Corp. II adds to the recent pipeline of specialized vehicles seeking to list on major exchanges.
The firm’s focus on life sciences aligns with broader trends in the sector, where precision health platforms and diagnostics are increasingly becoming targets for public market combinations. Recent deals in the space, such as the combination between GigCapital8 and quantum computing firm Quantismo, highlight the diverse range of sectors SPACs are currently targeting, though Frazier’s mandate remains specifically centered on biotechnology and healthcare assets.
Investors will be able to purchase the shares through the Nasdaq Capital Market once trading commences. The company has not disclosed a specific target company at this stage, as is standard for SPACs at the pricing phase. The offering is expected to provide the capital necessary to complete a qualifying business combination within the typical SPAC timeline, allowing private life sciences companies to access public equity markets through a merger rather than a traditional IPO.